CARDIOVASCULAR COMPLICATIONS OF ANTICANCER THERAPY: DEFINITION, ETIOLOGY, EPIDEMIOLOGY, PATHOGENESIS, CLASSIFICATION (PART I)


Cite item

Full Text

Abstract

The given review is devoted to the problem of the cardiotoxicity of chemotherapeutic agents. Modern cytostatics cause clinically significant manifestations of cardiotoxicity - myocardial injuries, reducing both quality and life expectancy of oncological patients. Many of chemotherapeutic agents can cause cardiovascular complications such as the development of the left ventricular dysfunction and heart failure, myocardial ischemia, arterial hypertension, thromboembolism, QT prolongation and arrhythmias. The toxic influence of the most often used chemotherapeutic agents on heart (antimetabolites, alkylating agents, platinum compounds, taxanes, vinca alkaloids, monoclonal antibodies, anthracycline antibiotics, topoisomerase and protein kinase inhibitors, immunomodulatory agents and cytokines) has been described. The results of recent studies on etiology, epidemiology, classification and pathogenesis are presented in the first part of review. Most attention is paid to recent research in pathogenesis of chemotherapy induced cardiotoxicity. Given the numerous aspects of cardiotoxicity are not completely studied yet, obviously the further researches are needed in this field.

About the authors

N. T Vatutin

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine; Donetsk, 83045, Ukraine

E. V Sklyannaya

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine; Donetsk, 83045, Ukraine

Mariam A. El-Khatib

M. Gorky Donetsk National Medical University

Email: el-khatib.mariam@yandex.ru
MD, Assistant Professor of the Department of Hospital Therapy; Donetsk, 83003,Ukraine Donetsk, 83003, Ukraine

G. G Taradin

M. Gorky Donetsk National Medical University; V.K. Gusak Institute of Emergency and Reconstructive Surgery

Donetsk, 83003, Ukraine; Donetsk, 83045, Ukraine

References

  1. Матяш М.Г., Кравчук Т.Л., Высоцкая В.В., Чернов В.И., Гольдберг В.Е. Индуцированная антрациклинами кардиотоксичность: механизмы развития и клинические проявления. Сибирский онкологический журнал. 2008; 6: 66-75.
  2. Снеговой А.В., Виценя М.В., Копп М.В., Ларионова В.Б. Практические рекомендации по коррекции кардиоваскулярной токсичности, индуцированной химиотерапией и таргетными препаратами. Злокачественные опухоли. 2015; s4: 369-78.
  3. Zamorano J.L., Lancellotti P., Muñoz D.R., Aboyans V., Asteggiano R. et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 2016; 37(36): 2768-801. doi: 10.1093/eurheartj/ehw21.
  4. Калинкина Н.В. Повреждение сердца антрациклинами. Донецк: Каштан; 2008.
  5. Ewer M.S., Swain S.M., Cardinale D., Fadol A., SuterT.M. Cardiac dysfunction after cancer treatment. Tex. Heart Inst. J. 2011; 38(3): 248-52.
  6. Yeh E.T., Bickford C.L. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 2009; 53(24): 2231-47. doi: 10.1016/j.jacc.2009.02.050.
  7. Curigliano G., Cardinale D., Suter T., Plataniotis G., de Azambuja E., Sandri M.T. et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann. Oncol. 2012; 23(Suppl. 7): vii155-66. doi: 10.1093/annonc/mds293.
  8. Lipshultz S.E., Franco V.I., Miller T.L., Colan S.D., Sallan S.E. Cardiovascular disease in adult survivors of childhood cancer. Annu. Rev. Med. 2015; 66: 161-76. doi: 10.1146/annurev-med-070213-054849.
  9. Chu T.F., Rupnick M.A., Kerkela R., Dallabrida S.M., Zurakowski D., Nguyen L. et al. Cardiotoxicity associated with tyrosinekinase inhibitor sunitinib. Lancet. 2007; 370(9604): 2011-9. doi: 10.1016/S0140-6736(07)61865-0.
  10. Hrdina R., Gersl V., Klimtova I., Simunek T., Machackova J., Adamcova M. Anthracycline-induced cardiotoxicity. Acta Med. (Hradec Kralove). 2000; 43(3): 75-82.
  11. Myers C., Gianni L., Zweier J., Muindi J., Sinha B.K., Eliot H. Role of iron in adriamycin biochemistry. Fed. Proc. 1986; 45(12): 2796-7.
  12. Miolo G.M., La Mura N., Nigri P., Murrone A., Da Ronch L., Viel E. et al. The cardiotoxicity of chemotherapy: New prospects for an old problem. Radiol. Oncol. 2006; 40(3): 149-61.
  13. Volkova M., Russell R. Anthracycline сardiotoxicity: Prevalence, рathogenesis and treatment. Curr. Cardiol. Rev. 2011; 7(4): 214-20. doi: 10.2174/157340311799960645.
  14. Page R.L. 2nd, O’Bryant C.L., Cheng D., Dow T.J., Ky B., Stein C.M. et al. Drugs that may cause or exacerbate heart failure. Circulation. 2016; 134(6): e32-69. doi: 10.1161/CIR.0000000000000426.
  15. Cummings J., Anderson L., Willmott N., Smyth J.F. The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer. 1991; 27(5): 532-5.
  16. Kim Y., Ma A.G., Kitta K., Fitch S.N., Ikeda T., Ihara Y. et al. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 2003; 63(2): 368-77.
  17. Yin X., Wu H., Chen Y., Kang Y.J. Induction of antioxidants by adriamycin in mouse heart. Biochem. Pharmacol. 1998; 56(1): 87-93.
  18. Bristow M.R., Billingham M.E, Mason J.W., Daniels J.R. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat. Rep. 1978; 62(6): 873-9.
  19. Pai V.B., Nahata M.C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000; 22(4): 263-302.
  20. Morandi P., Ruffini P.A., Benvenuto G.M., Raimondi R., Fosser V. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant. 2005; 35: 323-34. doi: 10.1038/sj.bmt.1704763.
  21. Селиверстова Д.В., Евсина О.В. Кардиотоксичность химиотерапии. Сердце. 2016; 15(1): 50-7. doi: 10.18087 / rhj.2016.1.2115.
  22. Cardinale D., Colombo A., Colombo N. Acute coronary syndrome induced by oral capecitabine. Can. J. Cardiol. 2006; 22(3): 251-3.
  23. Гендлин Г.Е., Емелина Е.И., Никитин И.Г., Васюк Ю.А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. Российский кардиологический журнал. 2017; 3: 145-54. doi: 10.15829/1560-4071-2017-3-145-154.
  24. Yeh E.T., Tong A.T., Lenihan D.J., Yusuf S.W., Swafford J., Champion C. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004; 109(25): 3122-31. doi: 10.1161/01.CIR.0000133187.74800.B9.
  25. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management. Eur. Heart J. 2013; 34(15): 1102-11. doi: 10.1093/eurheartj/ehs181.
  26. Крикунова О.В., Васюк Ю.А., Висков Р.В., Крикунов П.В., Иванова С.В., Коник В.А. Сердечные тропонины в выявлении кардиотоксичности у пациентов, подвергающихся химиотерапии. Российский кардиологический журнал. 2015; 12: 119-25. http://dx.doi.org/10.15829/1560-4071-2015-12-119-125.
  27. Senkus E., Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011; 37(4): 300-11. doi: 10.1016/j.ctrv.2010.11.001.
  28. Ewer M.S., O’Shaughnessy J.A. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin. Breast Cancer. 2007; 7(8): 600-7.
  29. Manrique C.R., Park M., Tiwari N., Plana J.C., Garcia M.J. Diagnostic strategies for early recognition of cancer therapeutics-related cardiac dysfunction. Clin. Med. Insights Cardiol. 2017; 11: 1-12. doi: 10.1177/1179546817697.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies